Sublicensing Payments. EYEFITE agrees to pay PHS a sublicensing payment of twenty percent (20%) of any monetary consideration received from each sublicense, but not including royalties on Net Sales for which royalties will only be due under Sub-Section (b) above. EYEFITE may credit Milestone Payments due under Sub-Section (c) above against any sublicensing payments due on consideration received by EYEFITE from any Sublicensee for any milestones achieved by a Sublicensee when such milestones are substantially similar to the milestones described above for Sub-Section (c).
Sublicensing Payments. Licensee shall pay Caltech the percentage as forth in the table below of any sublicensing payments that Licensee receives from sublicensing with respect to Exclusively Licensed Patent Rights, based on the most advanced stage of development of the sublicensed Licensed Product as follows: Stage of Licensed Product when Sublicensed Percentage of Sublicense Revenue *** *** *** *** *** *** *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. For clarity, such sublicensing payments specifically shall not include payments made by a sublicensee solely in consideration of: (a) equity or debt securities of Licensee (but including any premium above the fair market value of such equity or debt securities, which shall be subject to the percentage-based payments to Caltech); (b) to support research or development activities to be undertaken by or for Licensee; (c) upon the achievement by Licensee of specified milestones or benchmarks relating to the development of Licensed Products; (d) pilot studies; (e) performance-based milestones (but including milestones tied to sales or marketing performance, which shall be subject to the percentage-based payments to Caltech); (f) the license or sublicense of any intellectual property other than Caltech Technology under such sublicense (which portion attributable to the Caltech Technology and such other intellectual property shall be determined in good faith by Licensee); (g) products other than Licensed Products; or (h) reimbursement for patent or other out-of-pocket expenses.
Sublicensing Payments. On a product by product basis, TGTX shall pay to Rhizen a tiered percentage (ranging from *%) of all Sublicensing Payments (the “Sublicensing Milestones”) received by TGTX and its Affiliates from each Sublicensee throughout the term of the applicable Commercial Sublicensing Agreement, which percentage shall be equal to the percentage set forth on the chart below corresponding to the number of Patients to whom the Product has been administered in any Phase I, Phase II or Phase III Clinical Trial on the effective date of the Commercial Sublicensing Agreement (the “Applicable Percentage”). Such payments shall be made to Rhizen within forty-five (45) days following receipt by TGTX of any Sublicensing Payment made from and after the applicable event. For avoidance of doubt, during the time that such sublicensing payments are made under this Section 6.4.1, the payments described under Section 6.3.2 and Section 6.3.3 shall not apply in the territory which has been sublicensed. If at any time a Commercial Sublicensing Agreement is terminated or expires, Section 6.3.2 and Section 6.3.3 shall apply. “Patients dosed” in the table below refers to the total patients dosed with the Product, on a product-by-product basis, after the Effective Date of this Licensing Agreement. Event Clinical stage(s) % Share on Sublicensing 1 * patients dosed * 2 * patients dosed * 3 * patients dosed * 4 * patient dosed to NDA filing *
Sublicensing Payments. Licensee shall pay to Children’s **** of all remuneration received by Licensee for each sublicense of the rights to the Licensed Technology granted hereunder, including ****, but excluding ****. Sublicensing payments shall be made to Children’s by or on ****. Sublicensing payments expressly exclude ****. In no event will this Section 4.5 apply to any Change of Control of Licensee or its Affiliate or sublicensee or otherwise be deemed to trigger an obligation for Licensee or its Affiliate or sublicensee to pay any amount to Children’s under this Section 4.5.
Sublicensing Payments. Licensee shall pay to Research Institute **** of all remuneration received by Licensee for each sublicense of the rights to the Licensed Technology granted hereunder, including ****, but excluding ****. Sublicensing payments shall be made to Research Institute by or on ****. Sublicensing payments expressly exclude ****. In no event will this Section 4.5 apply to any Change of Control of Licensee or its Affiliate or sublicensee or otherwise be deemed to trigger an obligation for Licensee or its Affiliate or sublicensee to pay any amount to Research Institute under this Section 4.5.
Sublicensing Payments. COMPANY shall receive [***] percent ([***]%) of all Sublicensing Revenues received by DEBIOPHARM and its Affiliates subject to the credits set forth in Section 8.4 hereof. Payment of Sublicensing Payments shall be made to COMPANY within [***] days as of receipt by DEBIOPHARM or its Affiliate of Sublicensing Revenues.
Sublicensing Payments. Sublicensing Payments shall be paid by DEBIOPHARM to COMPANY within [***] days from receipt of Sublicensing Revenues by DEBIOPHARM or its Affiliates.
Sublicensing Payments. For each Antisense Drug Development sublicense issued by ISIS under this provision, ISIS will pay IDT or will obligate the Antisense Drug Development Sublicense Holder to pay IDT, the initial sublicensing fees and Royalties as established in Appendix A, attached, and to comply with or fulfill all necessary reporting and accounting obligations as defined in this Restated Agreement. ISIS's initial license payments (specifically the [***] payment and the optional [***] payment) made under this provision will be creditable against initial sublicensing fees and royalty payments owed to IDT pursuant to the issuance of Antisense Drug Development Sublicenses.
Sublicensing Payments. Adial shall pay to Foundation fifteen percent (15%) of Sublicensing Revenues. However, Adial shall pay a running royalty on Net Sales of Licensed Products by Sublicensee under the Running Royalties paragraph hereinabove, and not under this paragraph.
Sublicensing Payments. BeHealth shall pay to UVA LVG an amount equal to [***] of Sublicensing Revenues. BeHealth shall not pay a running royalty on Net Sales of Licensed Products by its Sublicensees.
